195 related articles for article (PubMed ID: 19080728)
41. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.
Van Lenten BJ; Wagner AC; Jung CL; Ruchala P; Waring AJ; Lehrer RI; Watson AD; Hama S; Navab M; Anantharamaiah GM; Fogelman AM
J Lipid Res; 2008 Nov; 49(11):2302-11. PubMed ID: 18621920
[TBL] [Abstract][Full Text] [Related]
42. The structure/function of apoprotein A-I mimetic peptides: an update.
Getz GS; Reardon CA
Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):129-33. PubMed ID: 24569554
[TBL] [Abstract][Full Text] [Related]
43. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
Diditchenko S; Gille A; Pragst I; Stadler D; Waelchli M; Hamilton R; Leis A; Wright SD
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2202-11. PubMed ID: 23868939
[TBL] [Abstract][Full Text] [Related]
44. Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease.
Navab KD; Elboudwarej O; Gharif M; Yu J; Hama SY; Safarpour S; Hough GP; Vakili L; Reddy ST; Navab M; Vaziri ND
Curr Pharm Des; 2011; 17(1):17-20. PubMed ID: 21222643
[TBL] [Abstract][Full Text] [Related]
45. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
[TBL] [Abstract][Full Text] [Related]
46. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.
Nguyen SD; Maaninka K; Lappalainen J; Nurmi K; Metso J; Öörni K; Navab M; Fogelman AM; Jauhiainen M; Lee-Rueckert M; Kovanen PT
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):274-84. PubMed ID: 26681753
[TBL] [Abstract][Full Text] [Related]
47. A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE
Gou S; Wang L; Zhong C; Chen X; Ouyang X; Li B; Bao G; Liu H; Zhang Y; Ni J
Br J Pharmacol; 2020 Oct; 177(20):4627-4644. PubMed ID: 32726461
[TBL] [Abstract][Full Text] [Related]
48. High-Density Lipoprotein Mimetics: a Therapeutic Tool for Atherosclerotic Diseases.
Ikenaga M; Higaki Y; Saku K; Uehara Y
J Atheroscler Thromb; 2016; 23(4):385-94. PubMed ID: 26830201
[TBL] [Abstract][Full Text] [Related]
49. Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.).
White CR; Datta G; Mochon P; Zhang Z; Kelly O; Curcio C; Parks D; Palgunachari M; Handattu S; Gupta H; Garber DW; Anantharamaiah GM
Vasc Dis Prev; 2009 Jan; 6():122-130. PubMed ID: 20084185
[TBL] [Abstract][Full Text] [Related]
50. Apolipoprotein A-I mimetic 4F alters the function of human monocyte-derived macrophages.
Smythies LE; White CR; Maheshwari A; Palgunachari MN; Anantharamaiah GM; Chaddha M; Kurundkar AR; Datta G
Am J Physiol Cell Physiol; 2010 Jun; 298(6):C1538-48. PubMed ID: 20219948
[TBL] [Abstract][Full Text] [Related]
51. Structure-function properties of hypolipidemic peptides.
Nagaoka S
J Food Biochem; 2019 Jan; 43(1):e12539. PubMed ID: 31353491
[TBL] [Abstract][Full Text] [Related]
52. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.
Imaizumi S; Navab M; Morgantini C; Charles-Schoeman C; Su F; Gao F; Kwon M; Ganapathy E; Meriwether D; Farias-Eisner R; Fogelman AM; Reddy ST
Circ J; 2011; 75(7):1533-8. PubMed ID: 21628835
[TBL] [Abstract][Full Text] [Related]
53. Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis.
Sharifov OF; Xu X; Gaggar A; Grizzle WE; Mishra VK; Honavar J; Litovsky SH; Palgunachari MN; White CR; Anantharamaiah GM; Gupta H
PLoS One; 2013; 8(5):e64486. PubMed ID: 23691230
[TBL] [Abstract][Full Text] [Related]
54. Lipid-Free Apolipoprotein A-I Reduces Progression of Atherosclerosis by Mobilizing Microdomain Cholesterol and Attenuating the Number of CD131 Expressing Cells: Monitoring Cholesterol Homeostasis Using the Cellular Ester to Total Cholesterol Ratio.
Kaul S; Xu H; Zabalawi M; Maruko E; Fulp BE; Bluemn T; Brzoza-Lewis KL; Gerelus M; Weerasekera R; Kallinger R; James R; Zhang YS; Thomas MJ; Sorci-Thomas MG
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27821400
[TBL] [Abstract][Full Text] [Related]
55. Apolipoprotein A-I (ApoA-I) mimetic peptide P2a by restoring cholesterol esterification unmasks ApoA-I anti-inflammatory endogenous activity in vivo.
Bucci M; Cigliano L; Vellecco V; D'Andrea LD; Ziaco B; Rossi A; Sautebin L; Carlucci A; Abrescia P; Pedone C; Ianaro A; Cirino G
J Pharmacol Exp Ther; 2012 Mar; 340(3):716-22. PubMed ID: 22171091
[TBL] [Abstract][Full Text] [Related]
56. Apolipoprotein A-I mimetic peptides.
Hovingh GK; Bochem AE; Kastelein JJ
Curr Opin Lipidol; 2010 Dec; 21(6):481-6. PubMed ID: 21042216
[TBL] [Abstract][Full Text] [Related]
57. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
[TBL] [Abstract][Full Text] [Related]
58. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.
Bailey D; Jahagirdar R; Gordon A; Hafiane A; Campbell S; Chatur S; Wagner GS; Hansen HC; Chiacchia FS; Johansson J; Krimbou L; Wong NC; Genest J
J Am Coll Cardiol; 2010 Jun; 55(23):2580-9. PubMed ID: 20513599
[TBL] [Abstract][Full Text] [Related]
59. The role of high-density lipoprotein in inflammation.
Navab M; Anantharamaiah GM; Fogelman AM
Trends Cardiovasc Med; 2005 May; 15(4):158-61. PubMed ID: 16099381
[TBL] [Abstract][Full Text] [Related]
60. Inflammatory lipids as a target for therapy in the rheumatic diseases.
McMahon M; Brahn E
Expert Opin Investig Drugs; 2008 Aug; 17(8):1213-24. PubMed ID: 18616417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
